| Multidisciplinary meeting on male breast cancer: summary and research recommendations LA Korde, JA Zujewski, L Kamin, S Giordano, S Domchek, WF Anderson, ... Journal of clinical oncology 28 (12), 2114, 2010 | 556 | 2010 |
| Allogeneic hematopoietic stem cell transplantation: complications and results IA Tabbara, K Zimmerman, C Morgan, Z Nahleh Archives of internal medicine 162 (14), 1558-1566, 2002 | 251 | 2002 |
| Male breast cancer in the veterans affairs population: a comparative analysis ZA Nahleh, R Srikantiah, M Safa, AR Jazieh, A Muhleman, R Komrokji Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 202 | 2007 |
| Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer A Montoya, CN Amaya, A Belmont, N Diab, R Trevino, G Villanueva, ... Oncotarget 8 (4), 6446, 2017 | 121 | 2017 |
| Complementary and alternative medicine in breast cancer patients Z Nahleh, IA Tabbara Palliative & supportive care 1 (3), 267-273, 2003 | 121 | 2003 |
| Hormonal therapy for male breast cancer: a different approach for a different disease ZA Nahleh Cancer treatment reviews 32 (2), 101-105, 2006 | 108 | 2006 |
| Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory Z Nahleh Future Medicine Ltd 4 (1), 15-21, 2008 | 102 | 2008 |
| Glut-1 expression correlates with basal-like breast cancer YR Hussein, S Bandyopadhyay, A Semaan, Q Ahmed, B Albashiti, ... Translational oncology 4 (6), 321-327, 2011 | 96 | 2011 |
| Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma S Sethi, FH Sarkar, Q Ahmed, S Bandyopadhyay, ZA Nahleh, A Semaan, ... Translational oncology 4 (4), 222-226, 2011 | 96 | 2011 |
| Tumor-infiltrating lymphocytes and PD-L1 expression in pre-and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial V Pelekanou, WE Barlow, ZA Nahleh, B Wasserman, YC Lo, ... Molecular cancer therapeutics 17 (6), 1324-1331, 2018 | 92 | 2018 |
| SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response … ZA Nahleh, WE Barlow, DF Hayes, AF Schott, JR Gralow, WM Sikov, ... Breast cancer research and treatment 158, 485-495, 2016 | 89 | 2016 |
| Triple negative breast cancer: updates on classification and treatment in 2021 M Bou Zerdan, T Ghorayeb, F Saliba, S Allam, M Bou Zerdan, M Yaghi, ... Cancers 14 (5), 1253, 2022 | 84 | 2022 |
| A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints D Fumagalli, PL Bedard, Z Nahleh, S Michiels, C Sotiriou, S Loi, ... The lancet oncology 13 (6), e240-e248, 2012 | 82 | 2012 |
| Complementary and alternative medicine use and its association with quality of life among Lebanese breast cancer patients: a cross-sectional study F Naja, RA Fadel, M Alameddine, Y Aridi, A Zarif, D Hariri, A Mugharbel, ... BMC complementary and alternative medicine 15, 1-10, 2015 | 74 | 2015 |
| Male breast cancer: a gender issue Z Nahleh, S Girnius Nature clinical practice Oncology 3 (8), 428-437, 2006 | 74 | 2006 |
| Heat shock proteins in cancer: targeting the ‘chaperones’ Z Nahleh, A Tfayli, A Najm, A El Sayed, Z Nahle Future medicinal chemistry 4 (7), 927-935, 2012 | 70 | 2012 |
| Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies C Juhász, Z Nahleh, I Zitron, DC Chugani, MZ Janabi, S Bandyopadhyay, ... Nuclear medicine and biology 39 (7), 926-932, 2012 | 69 | 2012 |
| Breast cancer in the United States: a cross-sectional overview N Bilani, EC Zabor, L Elson, EB Elimimian, Z Nahleh Journal of cancer epidemiology 2020, 2020 | 66 | 2020 |
| The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer A Montoya, A Varela-Ramirez, E Dickerson, E Pasquier, A Torabi, ... Biomedical journal 42 (3), 155-165, 2019 | 66 | 2019 |
| Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer YR Hussein, AK Sood, S Bandyopadhyay, B Albashiti, A Semaan, ... Human pathology 43 (10), 1638-1644, 2012 | 65 | 2012 |
